| Data |
Ora |
Fonte |
Titolo |
|---|
| 23/1/2025 | 22:39 | EDGAR2 | Form 8-K - Current report |
| 21/1/2025 | 13:00 | BW | Pulse Biosciences Announces Late-Breaking Data from its.. |
| 14/1/2025 | 14:59 | EDGAR2 | Form 8-K - Current report |
| 13/1/2025 | 23:26 | EDGAR2 | Form 8-K - Current report |
| 13/1/2025 | 13:00 | BW | Pulse Biosciences’ Nanosecond PFA Technology to be Featured.. |
| 10/1/2025 | 14:00 | BW | Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief.. |
| 03/1/2025 | 15:00 | BW | Pulse Biosciences To Present at the 43rd Annual J.P. Morgan.. |
| 23/12/2024 | 22:30 | BW | Pulse Biosciences, Inc. Announces Planned Redemption of.. |
| 20/12/2024 | 23:00 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 19/12/2024 | 14:00 | BW | Pulse Biosciences, Inc. Announces Election to Exercise.. |
| 17/12/2024 | 14:00 | BW | Pulse Biosciences Announces Publication in the Journal of.. |
| 06/12/2024 | 22:14 | EDGAR2 | Form 8-K - Current report |
| 26/11/2024 | 18:36 | EDGAR2 | Form 8-K - Current report |
| 31/10/2024 | 20:01 | EDGAR2 | Form 8-K - Current report |
| 31/10/2024 | 19:25 | BW | Pulse Biosciences Announces Positive Clinical Data Presented.. |
| 30/10/2024 | 21:07 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 30/10/2024 | 21:06 | EDGAR2 | Form 8-K - Current report |
| 30/10/2024 | 21:05 | BW | Pulse Biosciences Reports Business Updates and Third Quarter.. |
| 30/10/2024 | 21:02 | BW | Pulse Biosciences Announces Appointment of David Kenigsberg,.. |
| 21/10/2024 | 14:00 | BW | Pulse Biosciences Schedules Third Quarter 2024 Financial.. |
| 01/10/2024 | 01:38 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 19/8/2024 | 22:25 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 15/8/2024 | 22:18 | EDGAR2 | Form NT 10-Q - Notification of inability to timely file Form.. |
| 12/8/2024 | 23:10 | EDGAR2 | Form 8-K - Current report |
| 12/8/2024 | 22:15 | EDGAR2 | Form 8-K - Current report |
| 12/8/2024 | 22:05 | BW | Pulse Biosciences Reports Business Updates and Preliminary.. |
| 12/8/2024 | 22:01 | BW | Pulse Biosciences, Inc. Appoints Paul LaViolette to Its.. |
| 08/8/2024 | 15:09 | EDGAR2 | Form 8-K - Current report |
| 08/8/2024 | 14:00 | BW | Pulse Biosciences, Inc. Announces Successful Treatment of.. |
| 01/8/2024 | 22:05 | BW | Pulse Biosciences, Inc. Announces Participation in Upcoming.. |
| 29/7/2024 | 22:05 | BW | Pulse Biosciences Schedules Second Quarter 2024 Financial.. |
| 23/7/2024 | 03:06 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 15/7/2024 | 13:10 | EDGAR2 | Form 8-K - Current report |
| 15/7/2024 | 13:04 | EDGAR2 | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 15/7/2024 | 12:05 | EDGAR2 | Form S-3MEF - Registration adding securities to prior Form.. |
| 09/7/2024 | 15:12 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 09/7/2024 | 03:56 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 09/7/2024 | 03:54 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 08/7/2024 | 22:13 | EDGAR2 | Form 8-K - Current report |
| 08/7/2024 | 14:00 | BW | Pulse Biosciences, Inc. Announces Receipt of FDA.. |
| 03/7/2024 | 20:44 | BW | Pulse Biosciences, Inc. Announces the Closing of its Rights.. |
| 28/6/2024 | 14:00 | BW | Pulse Biosciences, Inc. Announces Preliminary Results for.. |
| 07/6/2024 | 22:16 | EDGAR2 | Form 8-K - Current report |
| 04/6/2024 | 22:05 | EDGAR2 | Form 424B2 - Prospectus [Rule 424(b)(2)] |
| 04/6/2024 | 22:04 | EDGAR2 | Form 8-K - Current report |
| 03/6/2024 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
| 31/5/2024 | 22:18 | EDGAR2 | Form SD - Specialized disclosure report |
| 28/5/2024 | 23:19 | EDGAR2 | Form POS AM - Post-Effective amendments for registration.. |
| 22/5/2024 | 20:07 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 22/5/2024 | 20:03 | EDGAR2 | Form 3 - Initial statement of beneficial ownership of.. |
Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
